Author of

• 10743

  +

  P1.10 - Poster Session 1 - Chemotherapy (ID 204)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10774

    +

    P1.10-031 - Platinum-based Therapy with Gemcitabine or Docetaxel in Advanced Non-Small Cell Lung Cancer: A retrospective analysis to evaluate differences in response due to Ethnicity (ID 1644)

    09:30 - 09:30  |  Author(s): L. Sultana
    • Abstract

    Background
    Lung cancer has one of the highest incidences and mortalities of cancer worldwide, majority being non-small cell lung carcinoma (NSCLC). Platinum-based doublet chemotherapy remains the standard regimen for the treatment of NSCLC, providing an overall median survival of 8-10 months. The most common regimens include cisplatin or carboplatin with gemcitabine, paclitaxel or docetaxel. A multicenter study noted ethnicity to be a particular prognostic factor where significant differences were observed in response rates between Asian and Caucasian patients (65% vs 31% respectively) who all received docetaxel (75 mg/m[2]) and carboplatin (AUC 6). To investigate any such differences in therapeutic response in Bangladeshi patients from previous trials, a retrospective analysis was performed to evaluate survival in Bangladeshi NSCLC patients from a single institution.

    Methods
    62 patient records, between January 2009 and March 2013, from Square Hospital, Bangladesh were eligible. For the gemcitabine-platinum (GP) arm, 30 patients received either gemcitabine (D1 and D8-1000mg/m[2]) and cisplatin (75 mg/m[2]) or gemcitabine (1000mg/m[2]) and carboplatin (AUC 5). For the docetaxel-platinum (DP) arm, 32 patients received either docetaxel (75mg/m[2]) and cisplatin (75mg/m[2]) or docetaxel (75mg/m[2]) and carboplatin (AUC 5). Median age for GP arm and DP arm were 61 and 57.5 years respectively. All the patients have received a minimum of 3 cycles of the respective regimen. Primary end-point was median overall survival (MOS)

    Results
    Analysis revealed a MOS of 14 months for GP (95% CI; 8.56-19.43) and 13 months (95% CI; 8.94-17.06) for DP. The 1 year survival percentages were 33.3% and 46.9%% for the GP and DP arms respectively; 2 year survival was only observed in GP arm (6.67%). Adverse neutropenic response was reported in only 4.8% (3) of all patients. This includes 2 cases of Grade III neutropenia in the DP arm and 1 Grade neutropenia in the GP arm.Figure 1

    Conclusion
    Though no statistical significance (p>0.05) was observed between the two groups, the MOS obtained for both groups were significantly longer than previous trials conducted for the respective regimens, thus confirming our hypothesis and highlighting the potential impact of ethnicity on therapeutic response. Therefore, ethnicity based trials should be conducted in the future to properly evaluate response of any particular therapeutic regimen.